Cor Vasa 2012, 54(9-10):e300-e304 | DOI: 10.1016/j.crvasa.2012.08.005

Hypertrophic cardiomyopathy - what is new?

Pavel Gregor*, Karol Čurila
III. interní-kardiologická klinika, Kardiocentrum 3. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha, Česká republika

Práce shrnuje některé nové poznatky týkající se hypertrofických kardiomyopatií. Zabývá se jejich současnou definicí, genetickými nálezy a vztahem k fenotypu onemocnění, dále otázkami výskytu, prognózy onemocnění. Diskutovány jsou i současné názory na léčbu, především s ohledem na provádění perkutánních septálních ablací a myektomií u těžce symptomatických, obstrukčních forem.

Keywords: Hypertrofické kardiomyopatie; Hypertrofie myokardu; Léčba hypertrofických kardiomyopatií; Perkutánní septální ablace; Septální myektomie

Received: August 1, 2012; Revised: August 10, 2012; Accepted: August 13, 2012; Published: September 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gregor P, Čurila K. Hypertrophic cardiomyopathy - what is new? Cor Vasa. 2012;54(9-10):e300-304. doi: 10.1016/j.crvasa.2012.08.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. P. Gregor, M. Černý, V. Červenka, et al., Hypertrofická kardiomyopatie, Scientia Medica, Praha, 1992.
    2. J. Veselka, A. Linhart, I. Šteiner, et al., Hypertrofická kardiomyopatie a příbuzná témata, Galén, Praha, 2006.
    3. P. Elliott, B. Anderson, E. Arbustini, et al., Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal 29 (2008) 270-276. Go to original source...
    4. J.A. Jarcho, W. McKenna, J.A. Pare, et al., Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. The New England Journal of Medicine 321 (1989) 1372-1378. Go to original source... Go to PubMed...
    5. S.D. Solomon, J.A. Jarcho, W. McKenna, et al., Familial hypertrophic cardiomyopathy is a genetically heterogenous disease. The Journal of Clinical Investigation 86 (1990) 993-100. Go to original source... Go to PubMed...
    6. A. Rosenzweig, H. Watkins, C.H. Seidman, et al, Preclinical diagnosis of familiar hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. The New England Journal of Medicine 325 (1991) 1753-1760. Go to original source... Go to PubMed...
    7. C.Y. Ho, Genetic considerations in hypertrophic cardiomyopathy, Progress in Cardiovascular Diseases 54 (2012) 456-460. Go to original source... Go to PubMed...
    8. K. Curila, L. Benesova, M. Penicka, et al, Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy, Acta Cardiologica 67 (2012) 23-29. Go to original source... Go to PubMed...
    9. K. Curila, L. Benesova, M. Penicka, et al., Low prevalence and variable clinical presentation of troponin I and troponin T genes mutations in hypertrophic cardiomyopathy, Genetic Testing and Molecular Biomarkers 13 (2009) 647-650. Go to original source... Go to PubMed...
    10. R. Alcalai, J.G. Seidman, C.E. Seidman, Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics, Journal of Cardiovascular Electrophysiology 19 (2008) 104-110. Go to original source...
    11. J.C. Moolman, V.A. Corfield, Posen B, et al., Sudden death due to troponin T mutation, Journal of the American College of Cardiology 29 (1997) 549-555. Go to original source... Go to PubMed...
    12. R. Anan, H. Shono, A. Kisanuki, et al., Patients with familiar hypertrophic T gene have variable cardiac morphologies and a favorable prognosis, Circulation 98 (1998) 391-397. Go to original source... Go to PubMed...
    13. B.J. Maron, J.M. Gardin, J.M. Flack, et al., Prevalence of hypertrophic cardiomyopathy in a general population of young adults, Circulation 92 (1995) 785-789. Go to original source... Go to PubMed...
    14. B.J. Maron, P. Spirito, M.J. Roman, et al., Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study), American Journal of Cardiology 93 (2004) 1510-1514. Go to original source... Go to PubMed...
    15. P. Gregor, P. Widimsky, V. Cervenka, Electrocardiographic changes can precede the development of myocardial hypertrophy in the setting of hypertrophic cardiomyopathy, International Journal of Cardiology 23 (1989) 335-341. Go to original source... Go to PubMed...
    16. B.J. Maron, W. McKenna, G.K. Danielson, et al., ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathya report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy), Journal of the American College of Cardiology 42 (2003) 1687-1713. Go to original source... Go to PubMed...
    17. M.S.Maron, I. Olivotto, C. Harrigan, et al., Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy, Circulation 124 (2011) 40-47. Go to original source... Go to PubMed...
    18. D. Zemánek, P. Tomašov, S. Homolová,et al., Sublingual isosorbide dinitrate for the detection of obstruction in hypertrophic cardiomyopathy, European Heart Journal 12 (2011) 684-687. Go to original source... Go to PubMed...
    19. B.J. Maron, W.C. Roberts, S.E. Epstein, Sudden death in hypertrophic cardiomyopathy: profile of 78 patients, Circulation 65 (1982) 1388-1394. Go to original source... Go to PubMed...
    20. W.J. McKenna, A.J. Camm, Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk, Circulation 80 (1989) 1489-1492. Go to original source... Go to PubMed...
    21. P.M. Elliot, J.R. Gimeno, R. Haman, et al., Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy, Heart 92 (2006) 785-791. Go to original source... Go to PubMed...
    22. B.J. Maron, I. Olivotto, P. Spirito, et al., Epidemiology of hypertrophic cardiomyopathy - related death: revisited in a large non-referral-based patient population, Circulation 102 (2000) 858-864. Go to original source... Go to PubMed...
    23. P. Sorajja, R.A. Nishimura, B.J. Gersh, et al., Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomypathy. Journal of the American College of Cardiology 54 (2009) 234-241. Go to original source... Go to PubMed...
    24. J.M. Dupuis, A. Tabib, P. Rex, et al., Sudden unexpected death of cardiac origin in the 6 to 18 years population. Pathological data. Role of the sport? How can we present it?, Archives de Pédiatrie: Une publication de la Société française de pédiatrie 12 (2005) 1204-1208. Go to original source... Go to PubMed...
    25. S.R. Ommen, Hypertrophic cardiomyopathy. Current Problems in Cardiology 36 (2011) 409-453. Go to original source... Go to PubMed...
    26. P. Gregor, M. Herold, J. Krupička, P. Widimský, Angiotensin-converting enzyme inhibitors could be useful in hypertrophic nonobstructive cardiomyopathy. Cor et Vasa 39 (1997) 17-23.
    27. D.S. Lim, S. Lutucuta, P. Bachireddy, et al., Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy, Circulation 103 (2001) 789-791. Go to original source... Go to PubMed...
    28. J. Krupička, M. Pěnička, P. Gregor, et al., Ovlivnění hypertrofie levé komory u pacientů s hypertrofickou neobstruktivní kardiomyopatií: výsledky multicentrické randomizované studie CHANCE XIV. Cor et Vasa 48 (2006) 55. Go to original source...
    29. M. Pěnička, J. Krupička, R. Kerekeš, et al., Candesartan use in hypertrophic and non-obstructive cardiomyopathy: double-blind, placebo-controlled, randomized, multicenter study, Circulation 116 (2007) 3392.
    30. M. Penicka, P. Gregor, R. Kerekes, et al., Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study Investigators, The effects of candesartan on left ventricular hypertrophy and function in non-obstructive hypertrophic cardiomyopathy: a pilot, randomized study, The Journal of Molecular Diagnostics 11 (2009) 35-41. Go to original source... Go to PubMed...
    31. J. Bytešník, P. Pařízek, D. Wichterle, et al., Doporučené postupy pro diagnostiku a léčbu komorových arytmií, Cor et Vasa 53 (2011) (Suppl. 1) 53-77. Go to original source...
    32. B.J. Maron, R.A. Nishimura, W.J. McKenna, et al., Assessment of permanent dual-chamber patient as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomypathy. A randomized, double-blind, crossover study (M-PATHY), Circulation 99 (1999) 2927-2933. Go to original source... Go to PubMed...
    33. S.D. Colan, Treatment of hypertrophic cardiomyopathy in childhood. Progress in Pediatric Cardiology 31 (2011) 13-19. Go to original source...
    34. I. Olivotto, S.R. Ommen, M.S. Maron, et al., Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial?, Journal of the American College of Cardiology 50 (2007) 831-834. Go to original source... Go to PubMed...
    35. S.R. Ommen, B.J. Maron, I. Olivotto, et al., Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, Journal of the American College of Cardiology 46 (2005) 470-476. Go to original source... Go to PubMed...
    36. N.G. Smedira, B.W. Lytle, H.M. Lever, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. The Annals of Thoracic Surgery 85 (2008) 127-133. Go to original source... Go to PubMed...
    37. C.J. McLeod, S.R. Ommen, M.J. Ackerman, et al., Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy, European Heart Journal 28 (2007) 2583-2588. Go to original source... Go to PubMed...
    38. J. Veselka, P. Tomašov, D. Zemánek, Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. The Canadian Journal of Cardiology 27 (2011) 763-767. Go to original source... Go to PubMed...
    39. P. Sorajja, U. Valeti, R.A. Nishimura, et al., Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy, Circulation 118 (2008) 131-139. Go to original source... Go to PubMed...
    40. V.L. Fernandes, C. Nielsen, S.F. Nagueh, et al., Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996-2007, Journal of the American College of Cardiology. Cardiovascular Interventions 1 (2008) 561-570. Go to original source... Go to PubMed...
    41. S. Agarwal, E.M. Tuzcu, M.Y. Desai, et al., Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy, Journal of the American College of Cardiology 55 (2010) 823-834. Go to original source... Go to PubMed...
    42. F.J. ten Cate, O.I. Soliman, M. Michels, et al., Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy. A word of caution, Circulation. Heart Failure 3 (2010) 362-369. Go to original source... Go to PubMed...
    43. 2011 ACCF/AHA guidelines of the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. A report of the American College of Cardiology foundation/American Heart Association task force on practice guidelines, Journal of the American College of Cardiology 58 (2011) 2703-2738. Go to PubMed...
    44. R.A. Leopardi, E.P. Kransdorf, D.L. Simel, et al., Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment, Circulation. Cardiovascular Interventions 3 (2010) 97-104. Go to original source... Go to PubMed...
    45. B.J. Maron, M. Yacoub, J.A. Dearani, Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomypathy: bring septal myectomy back for European patients, European Heart Journal 32 (2011) 1055-1058. Go to original source... Go to PubMed...
    46. M.A. Fifer, U. Sigwart, Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomypathy: alcohol septal ablation, European Heart Journal 32 (2011) 1059-1064. Go to original source... Go to PubMed...
    47. U.S. Valeti, R.A. Nishimura, D.R. Holme, et al., Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy, Journal of the American College of Cardiology 49 (2007) 350-357. Go to original source... Go to PubMed...
    48. J. Veselka, R. Duchonová, S. Prochazkova, et al., Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes, American Journal of Cardiology 95 (2005) 675-678. Go to original source... Go to PubMed...
    49. H.J. Kuhn, Optimizing catheter-based therapy of hypertrophic obstructive cardiomyopathy: Does alcohol dose matter? Canadian Journal of Cardiology 27 (2011) 668-670. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes